2017 Fiscal Year Final Research Report
Immunological assay for development of a novel treatment guideline in malignant melanoma
| Project/Area Number |
16K15551
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMAZAKI Naoya 国立がん研究センター中央病院, 皮膚腫瘍科, 科長 (70501873)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | がん免疫療法 / CD4+ T 細胞 / 制御性T細胞 |
|---|
| Outline of Final Research Achievements |
In this study, immunological responses associated with clinical responses by immune checkpoint inhibitors, particularly anti-PD-1 monoclonal antibodies (mAb) were investigated. Comprehensive analyses by CyTOF with peripheral blood samples revealed that the increase of CD27+Fas-CD4+ central memory T cells after anti-PD-1 mAb treatment was associated with favorable clinical courses. Additionally, the balance of immune responses in tumors corresponded to clinical responses; high effector CD8+ T cells in responders and high immune suppressive CD4+ regulatory T cells in non-responders, respectively. Prospective studies with larger cohorts should be the next step for developing a new treatment guideline.
|
| Free Research Field |
腫瘍学、免疫学
|
